Holocene Advisors
DNLI icon

Holocene Advisors’s Denali Therapeutics DNLI Stock Holding History

Holocene Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$100M Buy
3,905,225
+709,796
+22% +$14.6M 0.23% 117
2026
Q1 		$61.4M Buy
3,195,429
+42,695
+1% +$850K 0.15% 161
2025
Q4 		$52.1M Buy
3,152,734
+17,022
+0.5% +$287K 0.11% 203
2025
Q3 		$45.5M Buy
3,135,712
+2,732,540
+678% +$39.3M 0.1% 192
2025
Q2 		$5.64M Buy
+403,172
New +$5.67M 0.01% 356
2025
Q1 		– Sell
-199,072
Closed -$4.06M – 775
2024
Q4 		$4.06M Buy
199,072
+101,625
+104% +$2.6M 0.01% 430
2024
Q3 		$2.84M Buy
97,447
+38,405
+65% +$952K 0.01% 486
2024
Q2 		$1.37M Sell
59,042
-801,906
-93% -$15.4M 0.01% 578
2024
Q1 		$17.7M Buy
+860,948
New +$16.2M 0.06% 223

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Holocene Advisors's DNLI Position: Q2 2026 in Review

Holocene Advisors increased its Denali Therapeutics (DNLI) stake by 22% in Q2 2026, buying an estimated $14.6M and bringing the position to 3,905,225 shares worth $100M. The position accounts for 0.23% of the portfolio, ranked #117.

Holocene Advisors first reported a position in DNLI in Q1 2024 and has held it in 9 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Holocene Advisors held 3,905,225 shares of Denali Therapeutics worth $100M as of Q2 2026.
  • Holocene Advisors bought 709,796 Denali Therapeutics shares in Q2 2026, an estimated $14.6M.
  • Denali Therapeutics made up 0.23% of Holocene Advisors's portfolio in Q2 2026, its #117 holding.
  • Holocene Advisors first reported a position in Denali Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.